ASBMR Webinar Series on Bisphosphonates Now Available Online
Date: June 12, 2012
Last month, the U.S. Food and Drug Administration (FDA) weighed in on how long patients should take bisphosphonates for osteoporosis. In response, the ASBMR held two webinars: one on the efficacy and safety of bisphosphonates and another on case studies on the management of patients. Both webinars are now available online for viewing. Bisphosphonates are an important weapon against problems caused by osteoporosis and the benefits outweigh the risk of taking them. However, ASBMR urges physicians to consider each patient’s case individually since the optimal length of bisphosphonate therapy remains unknown and must be considered on a case-by-case basis. Patients whose fracture risk has clearly been reduced by bisphosphonates might be candidates for discontinuing the drug. However, individuals who after three to five years of taking bisphosphonates still have a high risk for fracture may want to remain on the medication because the risks of stopping treatment may not be the best option. For high-risk patients, there is strong data that the drug remains very useful in preventing fractures caused by osteoporosis. Read the full ASBMR press release.